← Leaderboards
Adam Bohr
Mycobacteria Therapeutics Corporation
$644,076
Attributed
$644,076
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $319.1K · FY2020–22$500K$375K$250K$125K$0
'20
'21
'22
Funding mix
By agency
NIH$644,076 · 1
By mechanism
R41$644,076 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Effector T Cell”
- Tomasz Nowakowski · University Of California, San Francisco$9,024,950
- Gary Fanger · Rise Therapeutics, Llc$8,686,361
- Crystal Mackall · Children'S Hosp Of Philadelphia$7,012,524
- William Karl Decker · Baylor College Of Medicine$5,675,036
- James Even Voss · Scripps Research Institute, The$5,423,867
- Lucia N Vojtech · University Of Washington$5,251,660
Research focus
Effector T CellAdultAnti-Inflammatory AgentsBaseAnxietyBehavioral ResponseBacteriaBrainCell LineCellsBehavioral AssayChemokineChronicClinical DevelopmentBone MarrowColoradoConditioned FearCountryCuesCytokineDendritic CellsDepressive SymptomsDiagnosisEnsure
Grant awards (3)
Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD$319,076
R41 · FY2022 · AT · contact PI
Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD$42,157
R41 · FY2021 · AT · contact PI
Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD$282,843
R41 · FY2020 · AT · contact PI